Relmada Therapeutics, Inc.

Relmada’s lead program REL‑1017 showed positive results in Phase II for major depressive disorder but failed to meet endpoints in two Phase III trials. The company has since shifted focus to new product acquisitions and pipeline expansion. NDV‑01 demonstrated strong proof-of-concept data in a Phase II study for non-muscle invasive bladder cancer with high rates of disease-free status. Sepranolone, recently acquired from Asarina Pharma, showed promising mid-stage results reducing tics in Tourette syndrome without significant side effects. A modified-release psilocybin formulation for obesity/metabolic disease has shown preclinical promise and will enter clinical trials soon[2][3][5][8].